Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Imidazo[1,2-A]Quinazolines As Novel, Potent Egfr-Tk Inhibitors: Design, Synthesis, Bioactivity Evaluation, and in Silico Studies Publisher Pubmed



Hasanvand Z1 ; Oghabi Bakhshaiesh T2 ; Peytam F3 ; Firoozpour L1 ; Hosseinzadeh E1 ; Motahari R1 ; Moghimi S3 ; Nazeri E2 ; Toolabi M4 ; Momeni F5 ; Bijanzadeh H6 ; Khalaj A1 ; Baratte B7, 8 ; Josselin B7, 8 Show All Authors
Authors
  1. Hasanvand Z1
  2. Oghabi Bakhshaiesh T2
  3. Peytam F3
  4. Firoozpour L1
  5. Hosseinzadeh E1
  6. Motahari R1
  7. Moghimi S3
  8. Nazeri E2
  9. Toolabi M4
  10. Momeni F5
  11. Bijanzadeh H6
  12. Khalaj A1
  13. Baratte B7, 8
  14. Josselin B7, 8
  15. Robert T7, 8
  16. Bach S7, 8, 9
  17. Esmaeili R2
  18. Foroumadi A1, 3

Source: Bioorganic Chemistry Published:2023


Abstract

Tyrosine protein kinases (TKs) have been proved to play substantial roles on many cellular processes and their overexpression tend to be found in various types of cancers. Therefore, over recent decades, numerous tyrosine protein kinase inhibitors particularly epidermal growth factor receptor (EGFR) inhibitors have been introduced to treat cancer. Present study describes a novel series of imidazo[1,2-a]quinazolines 18 as potential -inhibitors. These imidazoquinazolines (18a and 18o, in particular) had great anti-proliferative activities with IC50 values in the micromolar (µM) range against PC3, HepG2, HeLa, and MDA-MB-231 comparing with Erlotinib as reference marketed drug. Further evaluations on some derivatives revealed their potential to induce apoptotic cell death and cell growth arrest at G0 phase of the cell cycle. Afterwards, the kinase assay on the most potent compounds 18a and 18o demonstrated their inhibitory potencies and selectivity toward EGFR (with EGFR-IC50 values of 82.0 µM and 12.3 µM, respectively). Additionally, western blot analysis on these compounds 18a and 18o exhibited that they inhibited the phosphorylation of EGFR and its downstream molecule extracellular signal-regulated kinase (ERK1/2). However, the level of B-Actin phosphorylation was not changed. Finally, density functional theory calculations, docking study, and independent gradient model (IGM) were performed to illustrate the structure–activity relationship (SAR) and to assess the interactions between proteins and ligands. The results of molecular docking studies had great agreement with the obtained EGFR inhibitory results through in vitro evaluations. © 2023
Other Related Docs
5. Structure-Based Virtual Screening for Defeating Drug Resistant Form of Egfr Protein, Combinatorial Chemistry and High Throughput Screening (2016)